Andrew Booth, Chief Financial Officer at AbCellera Biologics Inc. (ABCL), bought 37,200 shares at $10.32 ($384K) on 2026-08-14, disclosed to the SEC on 2026-08-14.
CFO Andrew Booth purchased $383,904 worth of shares at $10.32, marking the largest insider purchase in the company's history. This significant buy by a C-suite executive signals confidence in the recent positive clinical data for ABCL635.
The stock is currently trading at $5.445, up 32.64% over the last 90 days but still down 19.69% from its 52-week high of $6.78.
Data for the ABCL635 Phase 2 program is expected in August following enrollment completion announced on Aug 13; the stock rallied 60.3% after strong results on Aug 12; and the company's fair value estimate was raised to $14.63 on Aug 12.
The stock faces a high short interest of 20.41% and is currently trading at a premium, with one analyst noting the stock could be 33% overvalued following its 172% year-to-date run.
Something here stands out, but not much.
| Filing → |
| ABCL | BUY | 2022-05-16 | $492K | — | Filing → |
| ABCL | BUY | 2021-11-15 | $993K | — | Filing → |
| ABCL | SELL | 2021-06-10 | $30.6M | — | Filing → |